The CXCR4 antagonist plerixafor (AMD3100) promotes proliferation of Ewing sarcoma cell lines in vitro and activates receptor tyrosine kinase signaling

BACKGROUND: The CXCR4 receptor antagonist plerixafor (AMD3100) is raising interest as an anti-cancer agent that disrupts the CXCL12-CXCR4 chemokine – receptor interaction between neoplastic cells and their microenvironment in tumor progression and metastasis. Here, we investigated plerixafor for ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Berning, Philipp, Schaefer, Christiane, Clemens, Dagmar, Korsching, Eberhard, Dirksen, Uta, Potratz, Jenny
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5960216/
https://www.ncbi.nlm.nih.gov/pubmed/29776413
http://dx.doi.org/10.1186/s12964-018-0233-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5960216/
https://www.ncbi.nlm.nih.gov/pubmed/29776413
http://dx.doi.org/10.1186/s12964-018-0233-2

Ejemplares similares